Health Care • Biotechnology: Pharmaceutical Preparations
$23.24 ▲ +0.59
(+2.61%)
MKT CAP: $11.61B • VOL: 3.49M
52W L $19 52W H $28
ELAN // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $4.71B | $4.44B | $4.42B |
| YoY Revenue Growth % | +6.2% | +0.5% | — |
| Gross Profit | $2.59B | $2.44B | $1.94B |
| Gross Margin % | 55.0% | 54.9% | 44.0% |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$273.8M | $398.8M | -$1.45B |
| Operating Margin % | -5.8% | 9.0% | -32.9% |
| Net Income (GAAP) | -$232.0M | $338.0M | -$1.23B |
| EBITDA (Normalized) | -$53.0M | $516.4M | -$1.29B |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | $560.0M | $541.0M | $271.0M |
| Capital Expenditures (CapEx) | $276.0M | $147.0M | $198.8M |
| Free Cash Flow (FCF) | $284.0M | $394.0M | $72.2M |
| FCF Margin % | 6.0% | 8.9% | 1.6% |
| Return on Invested Capital (ROIC %) | -2.4% | 3.2% | -29.8% |
| Cash & Short-Term Equivalents | $545.0M | $468.0M | $702.5M |
| Total Debt (Short + Long Term) | $3.06B | $4.28B | $1.49B |
| Total Stockholders' Equity | $6.55B | $6.10B | $3.07B |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR ELAN.